top of page

Tutkimusnäyttö eri



Schad, F., Thronicke, A., Hofheinz, R.-D., Matthes, H., & Grah, C. (2024). Patients with Advanced or Metastasised Non-Small-Cell Lung Cancer with Viscum album L. Therapy in Addition to PD-1/PD-L1 Blockade: A Real-World Data Study. Cancers, 16(8), 1609. 

Schad F, Steinmann D, Oei SL, Thronicke A, Grah C. Evaluation of quality of life in lung cancer patients receiving radiation and Viscum album L.: a real-world data study. Radiation Oncology 2023;18:47. DOI: s13014-023-02234-3.


Schibel S, Steinert M, Matthes H, Grah C. ACCEPT®: A Complementary Anthroposophical Program for the Palliative Treatment of Lung Cancer – Rationale and a Randomized Feasibility Study. Complement Med Res. 2021;28(4).  DOI: 10.1159/000516820.


Ostermann T, Appelbaum S, Poier D, Boehm K, Raak C and Büssing A. A Systematic Review and Meta-Analysis on the Survival of Cancer Patients Treated with a Fermented Viscum album L. Extract (Iscador): An Update of Findings. Complement Med Res. 2020 Jan 10:1-12. doi: 10.1159/000505202.

Kts. lisätietoja julkaisijan sivuilta

Thronicke A, Reinhold T, von Trott P, Grah C, Matthes B, Matthes H & Schad F. Cost-effectiveness of real-world administration of chemotherapy and add-on Viscum album L. therapy compared to chemotherapy in the treatment of stage IV NSCLC patients. Plos ONE. 2020;15(7):e0236426. Published 2020 Jul 27. doi: 10.1371/journal.pone.0236426


Thronicke A, Matthes B, von Trott P, Schad F & Grah C. Overall Survival of Non-metastasized NSCLC Patients Treated With Add-On Viscum album L. Integr Cancer Ther. 2020; doi: 10.1177/1534735420940384


Thronicke A, von Trott P, Kröz M, Grah C, Matthes B & Schad F. Health-Related Quality of Life in Patients with Lung Cancer Applying Integrative Oncology Concepts in a Certified Cancer Centre. Evid Based Complement Alternat Med. 2020;2020:5917382. Published 2020 May 10. doi: 10.1155/2020/5917382


Lee YG, Jung I, Koo DH, Kang DY, Oh TY, Oh S, Lee SS. Efficacy and safety of Viscum album extract (Helixor M) to treat malignant pleural effusion in patients with lung cancer. Supportive Care in Cancer 2019;27 (5): 1945-1949. DOI: 10.1007/s00520-018-4455-z​.

Schad F, Thronicke A, Steele M L, Merkle A, Matthes B, Grah C and Matthes H. Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis. PLoS One, 2018;13:e0203058. DOI: 10.1371/journal.pone.0203058 

Eom JS, Ahn HY, Mok JH, Lee G, Jo E-J, Kim M-H, Lee K, Kim KU, Park H-K, Lee MK. Pleurodesis using mistletoe extract delivered via a spray catheter during semirigid pleuroscopy for managing symptomatic malignant pleural effusion. Respiration 2018;95:177-181. DOI: 10.1159/000481869

Thronicke A, Oei SL, Grah C, Matthes B and Schad F. Nivolumab-induced toxicity profile in patients with advanced or metastasized lung cancer treated with Viscum album L. extracts. In Proceedings of the German Cancer Congress, DKK2018, 2018.

Werthmann PG, Saltzwedel G, Kienle GS. Minor regression and long-time survival (56 months) in a patient with malignant pleural mesothelioma under Viscum album and Helleborus niger extracts-a case report. J Thorac Dis 2017;9(12):E1064–E1070. doi:10.21037/jtd.2017.11.56

Kim S, Kim K-C, Lee C. Mistletoe (Viscum album) extract targets Axl to suppress cell proliferation and overcome cisplatin- and erlotinib-resistance in non-small cell lung cancer cells. Phytomedicine 2017;36:183-193. DOI: 10.1016/j.phymed.2017.09.017

Bar-Sela G, Wollner M, Hammer L, Agbarya A, Dudnik E and Haim N. Mistletoe as complementary treatment in patients with advanced non-small-cell lung cancer treated with carboplatin-based combinations: a randomised phase II study. Eur J Cancer, 2013;49:1058-1064 DOI: 10.1016/j.ejca.2012.11.007

Piao B K, Wang Y X, Xie G R, Mannsmann U, Matthes H, Beuth J and Lin H S. Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial. Anticancer Research 2004;24:303-310

Grossarth-Maticek R, Kiene H, Baumgartner SM, Ziegler R. Use of Iscador, an extract of European mistletoe (Viscum album), in cancer treatment: prospective nonrandomized and randomized matched-pair studies nested

within a cohort study. Altern Ther Health Med. 2001 May-Jun; 7(3): 57–66.

Dold U, Edler L, Maurer H, Muller D, Sakellariou B, Trendelenburg F, et al. Krebszusatztherapie beim fortgeschrittenen nichtkleinzelligen Bronchialkarzinom. Multizentrische kontrollierte Studie zur Prufung der

Wirksamkeit von Iscador und Polyerga. Stuttgart, New York: G. Thieme Verlag; 1991.

Salzer G, Danmayr E, Wutzlhofer F, Frey S. Adjuvante Iscador-Behandlung operierter  nicht kleinzelliger Bronchuskarzinome. Ergebnisse einer randomisierten Studie. Dtsch Z Onkol. 1991; 23(4): 94–8.

Salzer G, Havelec L. Rezidivprophylaxe bei operierten Bronchuskarzinompatienten mit dem Mistelpraparat Iscador: Ergebnisse

eines klinischen Versuchs aus den Jahren 1969-1971. Onkologie. 1978 Dec; 1(6): 264–7.

bottom of page